UroGen Pharma Ltd. (NASDAQ:URGN) Receives $38.20 Consensus Price Target from Brokerages

Shares of UroGen Pharma Ltd. (NASDAQ:URGN) have been given a consensus recommendation of “Buy” by the six research firms that are presently covering the company, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $38.20.

A number of research firms recently weighed in on URGN. D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of UroGen Pharma in a research note on Monday, March 10th. LADENBURG THALM/SH SH started coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price objective on the stock. Finally, HC Wainwright lowered their target price on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th.

Insiders Place Their Bets

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the sale, the general counsel now directly owns 26,468 shares in the company, valued at $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Mark Schoenberg sold 4,551 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the transaction, the insider now directly owns 145,666 shares in the company, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On UroGen Pharma

Several institutional investors have recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new position in UroGen Pharma during the 4th quarter valued at about $59,000. Lazard Asset Management LLC bought a new position in shares of UroGen Pharma during the fourth quarter valued at approximately $67,000. Aquatic Capital Management LLC purchased a new stake in shares of UroGen Pharma in the fourth quarter worth approximately $101,000. BNP Paribas Financial Markets lifted its stake in shares of UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after acquiring an additional 5,890 shares during the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new position in UroGen Pharma during the 4th quarter valued at $126,000. Institutional investors own 91.29% of the company’s stock.

UroGen Pharma Price Performance

Shares of UroGen Pharma stock opened at $11.53 on Friday. The stock has a market cap of $531.46 million, a P/E ratio of -3.66 and a beta of 1.12. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The stock’s fifty day moving average is $10.47 and its 200 day moving average is $11.60. UroGen Pharma has a one year low of $9.03 and a one year high of $20.70.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The company had revenue of $24.57 million during the quarter, compared to the consensus estimate of $25.25 million. Sell-side analysts anticipate that UroGen Pharma will post -3.12 earnings per share for the current year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.